Portal de investigação
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Böhm, M
- Butler, J
- Filippatos, G
- Pocock, SJ
- Abdin, A
- Mahfoud, F
- Brueckmann, M
- Gollop, ND
- Iwata, T
- Ponikowski, P
- Wanner, C
- Zannad, F
- Packer, M
- Anker, SD
- EMPEROR-Preserved Trial Comm Inves
Unidades de investigação
Abstract
BACKGROUND Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF) hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects and safety in relation to age have not been studied. OBJECTIVES The purpose of this study was to evaluate the interplay of age and empagliflozin effects in EMPERORPreserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). METHODS We grouped patients (n = 5,988) according to their baseline age (<65 years [n = 1,199], 65-74 years [n = 2,214], 75-79 years [n = 1,276], $80 years [n = 1,299]). We explored the influence of age on empagliflozin effects on CVD or HFH (primary outcome), total HFH, rate of decline in estimated glomerular filtration rate, health-related quality of life with the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score, and frequency of adverse events. RESULTS Considering only patients on placebo, the incidence of primary outcomes (P trend = 0.02) and CVD (P trend = 0.003) increased with age. Empagliflozin reduced primary outcomes (P trend = 0.33), first HFH (P trend = 0.22), and first and recurrent HFH (P trend = 0.11) across all age groups with an effect being similar at $75 years (P interaction = 0.22) or >80 years (P interaction = 0.51). Empagliflozin improved Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at week 52 and attenuated the decline of estimated glomerular filtration rate without age interaction (P = 0.48 and P = 0.32, respectively). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the age groups. CONCLUSIONS Empagliflozin reduced primary outcomes and first and recurrent HFH and improved symptoms across a broad age spectrum. High age was not associated with reduced efficacy or meaningful intolerability. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction [EMPERORPreserved]; NCT0305951) (J Am Coll Cardiol 2022;80:1-18) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Dados da publicação
- ISSN/ISSNe:
- 1558-3597, 0735-1097
- Tipo:
- Article
- Páginas:
- 1-18
- Link para outro recurso:
- www.scopus.com
Journal of the American College of Cardiology Elsevier USA
Citações Recebidas na Web of Science: 18
Citações Recebidas na Scopus: 38
Documentos
- Não há documentos
Filiações
Keywords
- Aged; Aged, 80 and over; Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Treatment Outcome; amino terminal pro brain natriuretic peptide; empagliflozin; benzhydryl derivative; empagliflozin; glucoside; acute kidney failure; adult; aged; Article; assessment of humans; atrial fibrillation; cardiovascular mortality; clinical assessment; Clinical Summary Score; controlled study; double blind procedure; estimated glomerular filtration rate; female; follow up; fracture; genital tract infection; heart atrium enlargement; heart atrium flutter; heart failure with preserved ejection fraction; heart left ventricle hypertrophy; hospitalization; human; hypoglycemia; hypotension; Kansas City Cardiomyopathy Questionnaire; macroalbuminuria; major clinical study; male; microalbuminuria; New York Heart Association class; outcome assessment; quality of life; randomized controlled trial; urinary tract infection; chronic disease; clinical trial; heart f
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Böhm M,Butler J,Filippatos G,Ferreira JP,Pocock SJ,Abdin A,Mahfoud F,Brueckmann M,Gollop ND,Iwata T,Ponikowski P,Wanner C,Zannad F,Packer M,Anker SD,EMPEROR I. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. J. Am. Coll. Cardiol. 2022. 80. (1):p. 1-18. IF:24,000. (1).
